Trial · NCT05764876
Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)
NCT05764876, Phase 3, Completed, Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws). Trials, record NCT05764876. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05764876
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)
- NCT number
- NCT05764876
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 383 participants, actual
- Lead sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- Conditions
- Yaws, Cutaneous Ulcer
- Interventions
- Linezolid Oral Tablet, Azithromycin Oral Tablet
- First posted
- 2023-03-13
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical resolution | 4 weeks after treatment | Proportion of patients with clinical resolution of yaws lesions (clinical cure). Assessment of clinical resolution defined as the complete healing of lesions at 4 weeks from treatment start. |
| Primary | Serological cure | 24 weeks after treatment | Proportion of patients with adequate serological response (serological cure). Assessment of sero-cure is described a negative non-treponemal line result (T2) on the Dual Path Platform (DPP) test at week 24. |
| Primary | Relapse | 24 weeks after treatment | Proportion of patients with relapse (recurrent episodes caused by the same strain) (molecular cure). Assessment of recurrence by molecular methods of Treponema pallidum ssp. pertenue (TPE) DNA in ulcer swab to determine relapse or reinfection within 24 weeks from treatment start. |
| Secondary | Lession (ulcer swab) TPE assessment | Baseline (before treatment) | Assessment of TPE strains by genomic molecular methods in ulcer swabs from patients with active yaws. |
| Secondary | Oral (oral swab) TPE assessment | Baseline (before treatment) | Assessment of TPE strains by genomic molecular methods in oral swabs from patients with active/latent yaws. |
| Secondary | Plasma TPE assessment | Baseline (before treatment) | Assessment of TPE strains by genomic molecular methods in plasma from patients with active/latent yaws. |
| Secondary | Allelic variation in recurrent cases | Baseline (before treatment) | Proportion of patients with allelic variation in TPE DNA in patients with recurrence or treatment failure. |
| Secondary | Identification of antibiotic resistance genotype. | 4 weeks after treatment | Proportion of patients with antibiotic resistance genotype. |
| Secondary | Identification of other causes of cutaneous ulcer | Baseline (before treatment) | Proportion of patients with selected known and unknown causes of cutaneous ulcers (CU). Assessment of etiological agents using polymerase chain reaction (PCR) for TPE, Haemophylus ducreyi (HD) and Streptoccocus pyogenes (SP). |
| Secondary | Safety of intervention (adverse events) | at 4 and up to 24 weeks after treatment. | Proportion of patients with adverse events |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05764876
GET https://conductscience.org/api/trials/v1/NCT05764876/registered